EX-2 3 exhibit_2.htm BL-8040 PRESENTATION Exhibit
Motixafortide (BL-8040) | ≥99%(HPLC) | Selleck | CXCR antagonist
For Bone Marrow Transplants in Blood Cancers, BL-8040 Shows Promise
BioLineRx's Motixafortide (BL-8040) Receives EC's ODD to Treat Pancreatic Cancer in Europe
JCM | Free Full-Text | The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies | HTML
BL- 8040 - A Novel CXCR4 Blocking Agent for Pancreatic Cancer - CancerConnect
BL- 8040 - A Novel CXCR4 Blocking Agent for Pancreatic Cancer - CancerConnect
BioLineRx reports rosy results from Phase2a trial for its cancer drug BL- 8040
Effects of BL-8040 and Pembrolizumab on the relative frequency of... | Download Scientific Diagram
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial | Nature Medicine
BioLineRx begins Phase IIa COMBAT trial of BL-8040 and Keytruda combination to treat pancreatic cancer - Clinical Trials Arena
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial | Nature Medicine
BioLineRx Reports Results of BL-8040 in Combination with Keytruda (pembrolizumab) in P-IIb Trial for Patients with Metastatic Pancreatic Cancer
BioLineRx Begins Triple Combination Arm of Phase 2a Pancreatic Cancer Trial | Equities News
BiolineRx Has Huge Upside In 2018 (NASDAQ:BLRX) | Seeking Alpha
Clinical trials of CXCR4 inhibitors in acute myeloid leukemia | Download Table
GENESIS: Phase III trial evaluating BL-8040 + G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma | Future Oncology
BL-8040 Combo Shows Good Disease Control in Pancreatic Cancer
Multiple Myeloma Stem Cell Therapy Candidate BL-8040 Enters Phase 3 Trial
BioLineRx: Expands Cancer Pipeline Significantly By Acquiring Novel Drug Candidate Ready For Human Trials (NASDAQ:BLRX) | Seeking Alpha
Motixafortide | C97H144FN33O19S2 - PubChem
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial | Request PDF
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial | Nature Medicine
